JX-594 (vaccine)

Please note that the content of this book primarily consists of articles available from Wikipedia or other free sources online. Jennerex invents the JX-594. To put it bluntly, Jennerex - Jennerex Biotherapeutics, is a private clinical-stage biotherapeutics company whose research focuses on the development and commercialization of targeted oncolytic immunotherapies. The vaccine JX-594 has as aim to treat solid tumors and severe cancers. Medical analysts have also states that JX-594 has proved to prevent the growth of new tumors and the development of malignancy. Various medical analysis and experiments have demonstrated that JX-594 also referred to as the Pexa-Vec, is a treatment which requires small doses that can potentially reduced tumor size and decreasing blood flow to tumors. Moreover, Pexa-Vec is an oncolytic immunotherapy designed to rapidly de-bulktumors via tumor cell lysis; activate an antivascular effect with rapid tumor vascular knockout; induce a durable immuneresponse against tumors...